Related references
Note: Only part of the references are listed.An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid
Ed Brewer et al.
BIOMEDICAL CHROMATOGRAPHY (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model
Barry Weatherley et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Influence of Chronic Renal Failure on Drug Metabolism and Transport
A. W. Dreisbach
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Recent developments in HIV and the kidney
Frank A. Post et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
Samantha Abel et al.
ANTIVIRAL THERAPY (2009)
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HIV-1 infection and the kidney: An evolving challenge in HIV medicine
Thushan I. De Silva et al.
MAYO CLINIC PROCEEDINGS (2007)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Share Paper
